BioNTech SE (BNTX)
NASDAQ: BNTX · IEX Real-Time Price · USD
86.71
-1.38 (-1.57%)
At close: Apr 25, 2024, 4:00 PM
88.17
+1.46 (1.68%)
After-hours: Apr 25, 2024, 7:52 PM EDT
BioNTech SE Employees
BioNTech SE had 6,133 employees on December 31, 2023. The number of employees increased by 1,603 or 35.39% compared to the previous year.
Employees
6,133
Change (1Y)
1,603
Growth (1Y)
35.39%
Revenue / Employee
$691,885
Profits / Employee
$168,542
Market Cap
20.61B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 6,133 | 1,603 | 35.39% |
Dec 31, 2022 | 4,530 | 1,448 | 46.98% |
Dec 31, 2021 | 3,082 | 1,141 | 58.78% |
Dec 31, 2020 | 1,941 | 631 | 48.17% |
Dec 31, 2019 | 1,310 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Koninklijke Philips | 69,656 |
Baxter International | 60,000 |
Cardinal Health | 48,000 |
Align Technology | 21,610 |
Zimmer Biomet Holdings | 18,000 |
Molina Healthcare | 18,000 |
STERIS | 17,100 |
Illumina | 13,360 |
BNTX News
- 13 hours ago - GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology - Reuters
- 3 days ago - BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024 - GlobeNewsWire
- 18 days ago - Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer - GlobeNewsWire
- 4 weeks ago - BioNTech gets US agency notice over default on COVID vaccine royalties - Reuters
- 5 weeks ago - BioNTech Earnings Fall Short of Estimates. The Stock Is Down. - Barrons
- 5 weeks ago - BioNTech Q4 earnings: COVID franchise to remain a notable cash contributor in 2024 - Invezz
- 5 weeks ago - BioNTech's stock sinks after earnings fall below expectations, hurt by writedowns of vaccine inventory - Market Watch
- 5 weeks ago - After earnings plunge, BioNTech pins hopes on cancer drug launches - Reuters